References
- Durrani OM, Tehrani NN, Marr JE. et al. Degree, duration, and causes of visual loss in uveitis. Br J Ophthalmol. 2004;88:1159–1162. doi:https://doi.org/10.1136/bjo.2003.037226.
- Foster CS, Kothari S, Anesi SD. et al. The ocular immunology and uveitis foundation preferred practice patterns of uveitis management. Surv Ophthalmol. 2016;1:1–17. doi:https://doi.org/10.1016/j.survophthal.2015.07.001.
- Jabs DA, Nussenblatt RB, Rosenbaum JT. Standardization of uveitis nomenclature for reporting clinical data. Results of the first international workshop. Am J Ophthalmol. 2005;140:509–516. doi:https://doi.org/10.1016/j.ajo.2005.03.057.
- Jabs DA, Rosenbaum JT, Foster CS. et al. Guidelines for the use of immunosuppressive drugs in patients with ocular inflammatory disorders: recommendations of an expert panel. Am J Ophthalmol. 2000;130:492–513. doi:https://doi.org/10.1016/s0002-9394(00)00659-0.
- Levy-Clarke G, Jabs DA, Read RW. et al. Expert panel recommendations for the use of anti-tumor necrosis factor biologic agents in patients with ocular inflammatory disorders. Ophthalmology. 2007;121:785–796 e783. doi:https://doi.org/10.1016/j.ophtha.2013.09.048.
- Cuchacovich M, Pacheco P, Diaz G, et al. Role of Azathioprine in steroid resistant non infectious ocular inflammatory diseases. Rev Med Chil. 2007;135(6):702‐707. doi:https://doi.org/10.4067/s0034-98872007000600003.
- Pacheco PA, Taylor SR, Cuchacovich MT, Diaz GV. Azathioprine in the management of autoimmune uveitis. Ocul Immunol Inflamm. 2008;16:161–165. doi:https://doi.org/10.1080/09273940802204519.
- Lee RWJ, Schewitz LP, Nicholson LB, Dayan CM, Dick AD. Steroid refractory CD4+ T cells in patients with sight-threatening uveitis. Investig Ophthalmol Vis Sci. 2009;50:4273–4278. doi:https://doi.org/10.1167/iovs.08-3152.
- Nussenblatt RB, Whitcup SM. Fundamentals and Clinical Practice: Expert Consult. Missouri: Mosby 2010. 480 p.
- Kawaguchi T, Horie S, Bouchenaki N, Ohno-Matsui K, Mochizuki M, Herbort CP. Suboptimal therapy controls clinically apparent disease but not subclinical progression of Vogt-Koyanagi-Harada disease. Int Ophthalmol. 2010;30:41–50. doi:https://doi.org/10.1007/s10792-008-9288-1.
- Zacks DN, Samson CM, Loewenstein J, Foster CS. Electroretinograms as an indicator of disease activity in birdshot retinochoroidopathy. Graefe’s archive for clinical and experimental ophthalmology. Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie. 2002;240:601–607. doi:https://doi.org/10.1007/s00417-002-0506-7.
- Gulati A, Sinha A, Jordan SC. et al. Efficacy and safety of treatment with rituximab for difficult steroid-resistant and dependent nephrotic syndrome: multicentric report. Clin J Am Soc Nephrol. 2010;5:2207–2212. doi:https://doi.org/10.2215/CJN.03470410.
- Munkholm P, Langholz E, Davidsen M, Binder V. Frequency of glucocorticoid resistance and dependency in Crohn’s disease. Gut. 1994;35:360–362. doi:https://doi.org/10.1136/gut.35.3.360.
- Niemeyer KM, Gonzales JA, Rathinam SR. et al. Quality-of-life outcomes from a randomized clinical trial comparing antimetabolites for intermediate, posterior, and panuveitis. Am J Ophthalmol. 2017;179:10–17. doi:https://doi.org/10.1016/j.ajo.2017.04.003.
- Moshirfar M, Somani AN, Motlagh MN, Ronquillo YC. Management of cataract in the setting of uveitis. Curr Opin Ophthalmol. 2020;31(1):3–9. doi:https://doi.org/10.1097/icu.0000000000000626.
- Goldhardt R, Rose BS. Uveitic macular edema: treatment update. Curr Ophthalmol Rep. 2016;4(1):30–37. doi:https://doi.org/10.1007/s40135-016-0090-3.
- Cunningham ET, Ferrara D, Mrejen S, Freund KB, Zierhut M. Imaging the choroid and choroidal neovascularization in eyes with inflammation. Ocul Immunol Inflamm. 2016;24(3):243–245. doi:https://doi.org/10.1080/09273948.2016.1180040.
- Pato E, Martin-Martinez MA, Castelló A, et al. Development of an activity disease score in patients with uveitis (UVEDAI). Rheumatol Int. 2016;37(4):647–656. doi:https://doi.org/10.1007/s00296-016-3593-1.
- Herbort CP, Tugal-Tutkun I, Neri P. Failure to integrate quantitative measurement methods of ocular inflammation hampers clinical practice and trials on new therapies for posterior uveitis. J Ocul Pharmacol Ther. 2017;33(4):263–277. doi:https://doi.org/10.1089/jop.2016.0089.
- Urzua CA, Guerrero J, Gatica H, Velasquez V, Goecke A. Evaluation of the glucocorticoid receptor as a biomarker of treatment response in Vogt-Koyanagi-Harada disease. Invest Ophthalmol Vis Sci. 2017;58(2):974–980. doi:https://doi.org/10.1167/iovs.16-20783.